Clinical trial · Observational
Brain Metastases in Norway - A Prospective Cohort Study
Brain Metastases in Norway - Improved Classification and Treatment. A Prospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The overall aim and primary outcome of this study will be a descriptive analysis of the current treatment practice of BM in Norway. Specifically, it may give answers to the following research questions: * What is the true incidence of BM in Norway? * How are patients with BM treated at present? * Do treatments differ between hospitals? * How do treatments impact quality of life of the patients? * Which factors (treatment, tumor and host variables) can explain disease control, survival, symptom relief, and general functions? * How can BM staging be improved?
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival after diagnosis of brain metastases
- timeFrame
- Time from diagnosis of brain metastases till death of any cause, assessed up to 12 months
- description
- Calculation of the overall survival times for each patient enrolled
Secondary outcomes (2)
- measure
- Treatment offered to patients diagnosed with brain metastases
- timeFrame
- 3 years
- description
- Description of treatment offered
- measure
- Changes in patient reported symptoms and quality of life items through EORTC questionnaire QLQ PAL15 and submodule BN20
- timeFrame
- Monthly up to 12 months after inclusion
- description
- Description of changes in patient reported outcomes through standardized questionnaires.European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for Cancer Patients receiving palliative care (EORTC QLQ-C15-PAL), covers items such as pain, physical and emotional functioning. The QLQ-BN20 contains questions on 7 single-item symptom scales (headaches, seizures, drowsiness, hair loss, itchy skin, leg weakness, and bladder control), and 4 multi-item scales (future uncertainty, visual disorder, motor dysfunction, and communication deficit). Patient's scores are translated into a scale from 1-100. A change of 10 points in one item is considered clinically significant.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Verified cancer diagnosis of solid tumors (based on radiological, histological/cytological or operative evidence). * Brain metastases verified by computer tomography (CT), contrast-enhanced magnetic resonance imaging (MRI), or surgical biopsies * Age ≥ 18 years * Able to comply with study procedures * Able to provide written informed consent after information in Norwegian Exclusion Criteria: * Primary brain tumors * Primary hematological malignancies (lymphomas, leukemias) * Previous diagnosis and/or treatment of BM * Unable to produce written informed consent after information in Norwegian
References
Publications (0)
Data not yet available